CNS drug development has been in turmoil in recent years.Ironically at a time when basic neuroscience is showing the greatest promise of treatments for many disorders with large unmet needs, the future of CNS drug development is under threat.We face multiple challenges.These include lack of understanding of the etiology and pathophysiology of CNS disorders, availability of validated drug targets, stagnant clinical trial designs, heterogeneous trial population, outcome measures issues, signal detection, medication compliance, and a host of other issues specific to each indication.Some of our challenges are due to the lack of the development of major breakthrough treatments.This talk will address how emerging technologies, innovation, collaboration and globalization are the key ingredients for the future success of CNS drug development.